About US
Contact us
-
Celgene's next-gen psoriasis drug dissed by German cost watchdogCelgene's ($CELG)Otezlahas been rolling along in the U.S. toward its aspirations as a blockbuster, picking up an approval for psoriatic arthritis before grabbing an FDA nod for the much wider use for2015/5/26
-
Merck's Keytruda, BMS' Opdivo score European nods to keep immuno-oncology race blazingMerck's ($MRK)Keytruda--which has been leapfrogged by Bristol-Myers Squibb ($BMY) rivalOpdivosince becoming the first PD-1 blocker to roll out in the U.S.--gained some regulatory ground in Europe on F2015/5/26
-
Valeant chief Pearson won't be scared off by M&A 'bubble'Valeant ($VRX) CEO J. Michael Pearson is plenty familiar with the pharma M&A space; after all, he's made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happ2015/5/25
-
Pfizer could buy GSK, but would Shire or Perrigo offer better targets?The speculation is building this week that Pfizer ($PFE) will either attempt another megadeal with GlaxoSmithKline ($GSK) or another run on AstraZeneca ($AZN). Either would cut Pfizer's tax rate and g2015/5/25
-
CVS Health gets more drug pricing clout with $12B deal for OmnicareGet ready for more of a squeeze on drugs used by seniors. CVS Health ($CVS) agreed to pay $12.7 billion for the pharmacy services company Omnicare ($OCR), which specializes in assisted living and long2015/5/22
-
Endo sews up $9.2B financing for Par Pharma buyoutEarlier this week, Endo ($ENDP) inked a pact to nabPar Pharmaceuticalfor $8 billion. But to do that, it'll need a loan, and it's agreed to a $9.275 billion loan package to back the acquisition. Deutsc2015/5/22
-
Hep C landscape shifts again as BMS combo nabs breakthrough tagGilead Sciences ($GILD) and AbbVie ($ABBV) caught a break for their hepatitis C treatments when the FDA rescinded breakthrough designations earlier this year for potential competitors being developed2015/5/21
-
ProPublica: Safety questions over GSK's Advair linger after years on the asthma throneU.S. regulators gave GlaxoSmithKline's ($GSK)Advairthe green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $8 billion in annual sales. But even afte2015/5/21
-
Relax, J&J--Eliquis may be surging, but Xarelto's safe for nowPfizer ($PFE) and Bristol-Myers Squibb's ($BMY) new-age anticoagulant,Eliquis, has been ramping up after a slow start, growing 2014 sales to $774 million from $146 million the year prior. But Johnson2015/5/19
-
Perrigo will talk tie-up if the price is right, CEO says--but Mylan has a ways to goPerrigo's ($PRGO) not opposed to striking a pact with Mylan ($MYL)--as long as the price is right. The bad news for its suitor, though, is that right now, it's nowhere close. As Perrigo CEO Joseph Pa2015/5/19